Brexit and the Healthcare Industry Implications for Pharma – the Story so Far

It may take up to five years for the healthcare industry to stabilize in the event of a ‘no deal’ Brexit. This is the consensus opinion among professionals surveyed in the pharmaceutical industry, according to GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘Brexit and the Healthcare Industry – Implications for Pharma – The Story So Far’, revealed that 66% of participants across the US, UK, and EU suggested that it would take more than three years for the UK to stabilize its healthcare industry, compared to only 9% of respondents who indicated that stabilization would occur in less than 12 months.

Scope

GlobalData’s Brexit and the Healthcare Industry – Implications for Pharma – the Story so far provides in-house analyst expertise on the results of a 10 minutes survey of 149 GlobalData Pharma clients and prospects which was fielded from February 4, 2019 to February 24, 2019. Participants answered questions about how they expected Brexit to affect the healthcare sector, both within and outside of the UK.

Components of the slide deck include:

  • Outcomes of Brexit – best and most likely outcomes of Brexit providing respondent mix by geography
  • Factors to Impact Healthcare—key factors to impact the post-Brexit UK healthcare industry providing respondent mix by region and seniority level as compared to Q1, Q2, and Q3
  • Impact on Research and Manufacturing — key factors to impact healthcare research and manufacturing in the UK post-Brexit providing respondent mix by region and seniority level as compared to Q1, Q2, and Q3
  • Impact on Corporate Strategy —level of impact of Brexit on corporate strategy providing respondent mix by region, seniority level, and headquarter location as compared to Q1, Q2, and Q3
  • Impact on Relocation — impact of Brexit on staff and headquarter relocation as indicated by resondents whose headquarters is located in the UK as compared to Q1, Q2, and Q3

Reasons to buy

Develop and design your corporate strategies post-Brexit through an in-house expert analysis of the key factors to impact the post-Brexit UK healthcare industry.

Develop business strategies by understanding the key factors to impact healthcare research and manufacturing in the UK post-Brexit.

Stay up to date on the industry’s changing sentiment towards Brexit from within the healthcare industry with quarterly surveys.

Identify emerging industry trends post-Brexit to gain a competitive advantage.

Table of Contents

1 Table of Contents (PowerPoint Deck)

1 Study Design

1.1 Abbreviations

1.2 Background, Objectives, and Design

1.3 Respondent Mix – Geography

1.4 ...

1 Table of Contents (PowerPoint Deck)

1 Study Design

1.1 Abbreviations

1.2 Background, Objectives, and Design

1.3 Respondent Mix – Geography

1.4 Respondent Mix – Seniority Level

1.5 Respondent Mix – Headquarters Location

2 Executive Summary

2.1 Key Findings

2.2 Change in Brexit Sentiment since Q3

3 Overview of UK Pharma Industry

3.1 The UK Pharma Industry – A Key Driver of the UK Economy

3.2 The UK as an Attractive Location for Clinical Trials

3.3 Brexit Timeline

4 Outcomes of Brexit

4.1 Best and Most Likely Outcomes of Brexit – No Brexit Is the Best Outcome but Not the Most Likely

4.2 Best and Most Likely Outcomes of Brexit – A Closer Look at Geography

4.3 At Least Three Years Necessary to Stabilize the UK Healthcare Industry in a “No Deal” Brexit

5 Factors to Impact Healthcare

5.1 Key Factors to Impact the UK Healthcare Industry After Brexit

5.2 Key Factors to Impact the UK Healthcare Industry After Brexit – A Closer Look at the Top Four Factors

6 Impact on Research and Manufacturing

6.1 Will Healthcare Research and Manufacturing Be Impacted Following Brexit? – Respondent Mix by Location

6.2 Will Healthcare Research and Manufacturing Be Impacted Following Brexit? – Respondent Mix by Seniority Level

6.3 Why the UK WILL Be an Attractive Destination for Healthcare Companies

6.4 Why the UK WILL NOT Be an Attractive Destination for Healthcare Companies

6.5 Is the UK as an Attractive Destination for Healthcare Research and Manufacturing? – In Their Words

7 Impact on Corporate Strategy

7.1 The Impact of Brexit on Corporate Strategy

7.2 The Impact of Brexit on Corporate Strategy, by Location – A Closer Look at the Numbers

7.3 The Impact of Brexit on Corporate Strategy, by Seniority Level

7.4 How Has Brexit Most Influenced Corporate Strategy? – Investing Resources into Managing the Potential Impact of Brexit Is a Major Concern

7.5 How Has Brexit Most Influenced Corporate Strategy? – In Their Words

8 Impact on Relocation

8.1 Potential of Relocation of Staff Due to Brexit – All Respondents

8.2 Potential of Relocation of Staff Due to Brexit – A Closer Look at Geography and Seniority Level

8.3 Relocation of Headquarters Unlikely After Brexit

9 Summary of Key Findings

10 Appendix

10.1 Related and Upcoming Reports

10.3 Sources

10.4 About the Authors

10.5 About Thematic Research

10.6 About Thematic Reports

10.7 About GlobalData

10.8 Contact Us

10.9 Disclaimer

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

GlobalData's Pharma eTrack has helped get me get a strong starting point for understanding our competitive landscape, building forecasts, and valuing programs

  Glenmark Pharmaceuticals, Inc. USA